ReviewPharmaceutical nanotechnology2019
Drug Combinations in Breast Cancer Therapy.
Review in Pharmaceutical nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 201 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
Photobiomodulation for Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer
Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals
Who cites it
201 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Current evidence on circRNAs as potential theranostic markers for detecting chemoresistance in breast cancer: a systematic review and meta‑analysis.Scientific reports · 2022Pooled it
- Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis.Clinics (Sao Paulo, Brazil) · 2021Pooled it
- Omission of dexamethasone in prophylaxis for highly emetogenic chemotherapy in patients with breast cancer.Einstein (Sao Paulo, Brazil) · 2025Trial
- Naringin Potentiates Docetaxel-Induced Apoptosis in Breast Cancer Cells via Transient Interaction with the TUBB3 GTP-Binding Site.Cell biochemistry and biophysics · 2026Article
- Multi-GraphDDI: Multi-Feature Fusion and Interaction for Graph-Based Drug-Drug Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Cephaeline promotes ferroptosis in breast cancer via p53/SLC7A11/GPX4 axis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.Journal of clinical medicine · 2026Review
- An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer.Cells · 2026Review
- Systematic interrogation of drug sensitivities in melanoma reveals potent synergistic and antagonistic drug combinations with translational potential.Communications medicine · 2026Article
- DisenKGE-DDI: A Knowledge Graph Embedding Framework Based on Disentangled Graph Attention Networks for Drug-Drug Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- BSA-Based Nanoparticles for Dual Loading of Pazopanib and Enzalutamide: Formulation Optimization and In Vitro Evaluation in Breast Cancer Cells.Pharmaceutics · 2026Article
- Synergistic anticancer effects of tamoxifen in combination with fisetin and chrysin on breast cancer cells: insights into viability, migration, and apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Modulation of breast cancer progression in high-altitude hypoxia by Tongqiaohuoxue Decoction via HIF-1α/VEGF signaling.Discover oncology · 2026Article
- Metformin potentiates DSF/Cu-loaded pluronic nanoparticles to improve therapeutic efficacy in triple-negative breast cancer.BMC biotechnology · 2026Article
- UniSyn: a multi-modal framework with knowledge transfer for anti-cancer drug synergy prediction.Genome biology · 2026Article
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model.Scientific reports · 2026Article
- The smoothing factor in breast intensity-modulated radiotherapy: dosimetric impact and a predictive model of plan acceptability.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
141 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Breast cancer therapy involves a multidisciplinary approach comprising surgery, radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires maximum therapeutic efficacy, with minimal undesirable effects to ensure a good quality of life for patients. The carefully selected combination of therapeutic interventions provides patients with the opportunity to derive maximum benefit from therapy while minimizing or eliminating recurrence, resistance and toxic effects, as well as ensuring that patients have a good quality of life. This review discusses therapeutic options for breast cancer treatments and various combinations that had been previously exploited. The review will also give an insight into the potential application of the nanotechnology platform for codelivery of therapeutics in breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.